EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effect of the Multi‐Strain Probiotic SYN ‐53 in the Management of Allergic Rhinoconjunctivitis

Karl-Christian Bergmann, Torsten Zuberbier iD

Allergy · 2025

DOI: 10.1111/all.16634 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, 2025. Verfasst von Karl-Christian Bergmann und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Allergology, Charité Universitätsmedizin, Berlin, Germany. Hauptthemen laut MEDLINE: Probiotics, Conjunctivitis, Allergic, Rhinitis, Allergic, Rhinitis, Allergic, Seasonal. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Synformulas.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Dysbiosis is increasingly linked to allergy development. This study evaluates the efficacy of the multi‐strain probiotic SYN‐53 in the management of allergic rhinoconjunctivitis (ARC). Eighty‐four subjects with confirmed grass pollen allergy underwent up to three bi‐weekly 3‐day intake cycles with SYN‐53 or placebo. After each cycle, subjects were exposed to grass pollen in an allergen exposure chamber. ARC symptoms were assessed using the Total Symptom Score (TSS) before and after each use of SYN‐53. After one intake cycle, SYN‐53 already showed a trend towards greater efficacy over placebo, which became significant after two cycles (ΔTSS MAX : −3.44 ± 0.42 vs. −1.87 ± 0.37; p = 0.0067), with 38% vs. 24% symptom relief. In subjects with moderate to severe symptoms, SYN‐53 was already significantly superior after one single intake cycle and improved further after two cycles (ΔTSS MAX : −4.78 ± 0.51 vs. −2.43 ± 0.47; p = 0.0014), with 45% vs. 26% symptom relief. SYN‐53 is effective in the management of ARC, highlighting the role of bacterial diversity and dosage in probiotic nutritional supplements.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProbioticsConjunctivitis, AllergicRhinitis, AllergicRhinitis, Allergic, SeasonalHumansAdultFemaleMaleTreatment OutcomeYoung AdultMiddle AgedPollenAllergensDisease Management

Stichwörter der Autor:innen

allergen exposure chamberallergic rhinitisallergic rhinoconjunctivitismicrobiomeprobiotic

Substanzen

Allergens

Autor:innen und Institutionen

  • Institute of Allergology, Charité Universitätsmedizin, Berlin, Germany.
  • Corporate Member of Freie Universität Berlin, Humboldt Universität zu Berlin, Berlin, Germany.
  • Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany.

ORCID-Profile: Torsten Zuberbier

Förderung

  • Synformulas

Zitieren

APA

Bergmann, K. C., & Zuberbier, T. (2025). Effect of the Multi‐Strain Probiotic SYN ‐53 in the Management of Allergic Rhinoconjunctivitis. Allergy. https://doi.org/10.1111/all.16634

Vancouver

Bergmann KC, Zuberbier T. Effect of the Multi‐Strain Probiotic SYN ‐53 in the Management of Allergic Rhinoconjunctivitis. Allergy. 2025. doi:10.1111/all.16634

BibTeX
@article{Bergmann2025,
  author = {Bergmann, Karl-Christian and Zuberbier, Torsten},
  title = {Effect of the Multi‐Strain Probiotic SYN ‐53 in the Management of Allergic Rhinoconjunctivitis},
  journal = {Allergy},
  year = {2025},
  doi = {10.1111/all.16634}
}
Kostenlos starten →